Factors that influence recruitment to COVID-19 vaccine trials: a qualitative evidence synthesis.
Biesty L. et al, (2024), Trials, 25
Therapeutics for Nipah virus disease: a systematic review to support prioritisation of drug candidates for clinical trials.
Chan XHS. et al, (2024), Lancet Microbe
Autochthonous Human Babesia divergens Infection, England.
Zabala GA. et al, (2024), Emerg Infect Dis, 30, 2165 - 2168
Nipah Virus Therapeutics: A Systematic Review to Support Prioritisation for Clinical Trials
Chan XHS. et al, (2024)
Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group None., (2024), Lancet Child Adolesc Health, 8, 190 - 200
Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group None., (2023), Lancet Diabetes Endocrinol, 11, 905 - 914
Factors that impact on recruitment to vaccine trials in the context of a pandemic or epidemic: a qualitative evidence synthesis.
Meskell P. et al, (2023), Cochrane Database Syst Rev, 9
Raising awareness of antimicrobial resistance: development of an 'antibiotic footprint calculator'.
Prapharsavat R. et al, (2023), J Antimicrob Chemother, 78, 1317 - 1321
Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group. Electronic address: recoverytrial@ndph.ox.ac.uk None. and RECOVERY Collaborative Group None., (2023), Lancet, 401, 1499 - 1507
Zinc supplementation for preventing mortality, morbidity, and growth failure in children aged 6 months to 12 years.
Imdad A. et al, (2023), Cochrane Database Syst Rev, 3
Cardiovascular Concentration-Effect Relationships of Amodiaquine and its Metabolite Desethylamodiaquine: Clinical and Pre-clinical Studies.
Chan XHS. et al, (2022), Br J Clin Pharmacol
Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis.
RECOVERY Collaborative Group None., (2022), Lancet, 400, 359 - 368
Reducing broad-spectrum antibiotic use in intensive care unit between first and second waves of COVID-19 did not adversely affect mortality.
Chan XHS. et al, (2022), J Hosp Infect, 124, 37 - 46
Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group None., (2022), Lancet, 399, 665 - 676
Factors that impact on recruitment to vaccine trials during a pandemic or epidemic: a qualitative evidence synthesis
Meskell P. et al, (2022), Cochrane Database of Systematic Reviews, 2022
Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group None., (2022), Lancet, 399, 143 - 151
Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group None., (2021), Lancet Respir Med, 9, 1419 - 1426
935. A Hospital Cluster of the Emerging Drug-resistant Yeast Saprochaete clavata
Chan XHS. et al, (2021), Open forum infectious diseases, 8, S560 - S560
Risk factors associated with bloodstream infections among critically ill patients with COVID-19.
McMillan T. et al, (2021), J Infect, 83, e1 - e3